Healios

What Healios does

Healios K.K. (TSE Growth: 4593) is a Japanese clinical-stage biotechnology company researching, developing, and manufacturing cell and regenerative medicine products for advanced medical treatments. The company operates a dual-platform model anchored on a somatic stem cell therapy (MultiStem / HLCM051 / invimestrocel) and an induced pluripotent stem cell (iPSC)-derived therapy platform. MultiStem is a bone marrow-derived allogeneic somatic stem cell product administered intravenously for acute ischemic stroke and acute respiratory distress syndrome (ARDS), and has received FDA Fast Track and RMAT designations as well as Japan's Sakigake Designation. The iPSC platform encompasses gene-edited eNK cells (engineered with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complexes) for solid tumor immunotherapy, hypoimmunogenic Universal Donor Cells (UDCs), iPSC-derived retinal pigment epithelium (RPE) cells for age-related macular degeneration, and 3D liver organ buds for liver disease.

Healios is pre-revenue with no approved products on the market and does not yet generate commercial sales. Its revenue model is described as one-time license oriented toward future product commercialization, expected to combine direct sales, licensing, and channel partnerships. Manufacturing capability is secured through Minaris (a contract manufacturing organization with a proprietary 50L bioreactor-based invimestrocel process), and a Basic Business Alliance Agreement with Alfresa Corporation (June 2024) establishes a potential distribution channel in Japan. Joint development is structured via Sighregen Co., Ltd. (a joint venture with Sumitomo Pharma for RPE/AMD products), RACTHERA Co., Ltd. (AMD/RPE tear co-development), and wholly-owned subsidiaries ProcellCure Inc. (ARDS) and Akatsuki Therapeutics Inc. (eNK cells). The company was founded in 2011, listed on the Tokyo Stock Exchange in 2015, and is headquartered in Tokyo with research operations at the Kobe Research Institute and a North American subsidiary (Healios NA, Inc., established February 2018).

Target indications address large unmet medical needs: approximately 230,000-330,000 ischemic stroke patients per year in Japan and over 5.26 million globally; approximately 28,000 ARDS patients per year in Japan with 30-58% mortality; solid tumors accounting for approximately 90% of cancer deaths in Japan; and liver diseases including approximately 56,000 cirrhosis patients and approximately 30 urea cycle defect patients per year in Japan. Healios has secured proprietary positions through the April 2024 acquisition of substantially all Athersys assets (gaining full global MultiStem rights), the RIKEN-licensed RPE cell patent estate, and in-house development of UDCs and eNK cells. As of December 31, 2025, the company employed 66 staff, held paid-in capital of 2,572 million yen, and had a cash position exceeding 10 billion yen following a January 2026 capital raise of approximately 6.3 billion yen.

Name

Healios

Legal name

HEALIOS K.K.

Website

https://healios.co.jp

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Healios is a Japanese clinical-stage biotechnology company developing regenerative medicine therapies on dual somatic stem cell (MultiStem for stroke and ARDS) and iPSC-derived (eNK cells, Universal Donor Cells, RPE cells, liver organ buds) platforms, targeting large unmet-need indications ahead of commercialization.

Ownership category

akta.pro rank

Product category

Cell Therapy & Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Regenerative medicine
• Cell therapy
• IPSC technology
• Stem cell therapy
• Biopharmaceutical development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Regenerative Medicine Product Revenue: Healios is pre-revenue and has not yet commercialized any products. The company is focused on developing its pipeline of regenerative medicine products (iPSC-derived therapies and MultiStem) through clinical trials toward regulatory approval in Japan and globally. Revenue is expected to come from product sales following approval.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Healios is a Japanese biotechnology company developing regenerative medicine products using two proprietary technology platforms. Its somatic stem cell platform (MultiStem/HLCM051) targets ischemic stroke and acute respiratory distress syndrome (ARDS), while its iPSC-based platform advances eNK cells for solid tumors, Universal Donor Cells (UDCs), retinal pigment epithelial (RPE) cells for age-related macular degeneration (AMD), and three-dimensional liver organ buds for liver disease.

Product overview

Healios is a Japanese biotechnology company developing a dual-platform regenerative medicine portfolio comprising somatic stem cell therapies and iPSC-based therapies. Its somatic stem cell platform is anchored by MultiStem (HLCM051 / invimestrocel), a bone marrow-derived cell therapy product administered intravenously for ischemic stroke and ARDS, now in late-stage clinical development with Fast Track and RMAT designations. Its iPSC platform encompasses multiple product candidates including eNK cells (gene-edited NK cells for solid tumor immuno-oncology), Universal Donor Cells (UDCs, hypoimmunogenic iPS cells for broad regenerative medicine applications), iPSC-derived RPE cell transplantation for age-related macular degeneration, and liver organ buds for liver disease. The company operates through subsidiaries including Healios NA Inc., Saisei Ventures, ProcellCure Inc., and Akatsuki Therapeutics Inc.

Differentiator

Problem solved

Functional benefit

Brands

• eNK cells: Gene-edited iPSC-derived NK cells for cancer immunotherapy with enhanced killing abilities against solid tumors
• Universal Donor Cells (UDCs)
• MultiStem (HLCM051)

Products and services

• MultiStem (HLCM051 / Invimestrocel)

Quantifiable outcome

• ONE-BRIDGE trial for ARDS showed favorable efficacy and safety results at 90th and 180th day evaluations
• +4 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered moderate, minor and core.

• Akatsuki Therapeutics, Inc.moderateStrategic or Co-development Partner · 1 January 2025Subsidiary established in January 2025 for joint research and development of eNK cells. Akatsuki Therapeutics and Healios are jointly developing eNK cell products, with joint research presented at AACR Annual Meeting 2026.
• Alfresa CorporationmoderateChannel Partner/ Reseller/ Distributor · 1 June 2024Healios entered into a Basic Business Alliance Agreement and Bond Purchase Agreement with Alfresa Corporation in June 2024. Alfresa is a major Japanese pharmaceutical wholesaler, positioning this as a potential distribution and commercial partnership arrangement in the Japanese market.
• ProcellCure, Inc.minorStrategic or Co-development Partner · 1 July 2023Subsidiary established in July 2023 to promote the development of ARDS treatments. ProcellCure focuses on the development and commercialization of cell therapy products for ARDS.
• Northwestern UniversityminorStrategic or Co-development Partner · 1 April 2023Research collaboration led by Dr. A.J. Matsuoka at Northwestern University confirming that otic neural progenitor cells differentiated from Healios UDCs showed enhanced survival after cochlear transplantation compared to unmodified cells. A paper was published in Stem Cell Research & Therapy.
• Universal Cells Inc.minorStrategic or Co-development Partner · 1 April 2016Healios entered into a collaborative research agreement with Universal Cells Inc. in April 2016 regarding gene editing strategies. Universal Cells' gene editing approach was published in Nature Biotechnology in May 2017. Healios subsequently developed its own UDC platform.
• Athersys, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2016Healios signed a license agreement with Athersys, Inc. in January 2016 for the development and commercialization of MultiStem (HLCM051) for ischemic stroke in Japan. In May 2018, Healios acquired the MultiStem license and obtained bank financing. In April 2024, Healios acquired substantially all assets of Athersys, gaining full ownership of MultiStem rights globally.
• Sighregen Co., Ltd. (Sumitomo Pharma Joint Venture)coreStrategic or Co-development Partner · 1 February 2014Joint venture company established with Sumitomo Pharma Co., Ltd. (originally Sumitomo Dainippon Pharma) in February 2014 for the development and commercialization of regenerative medicine products, particularly RPE cells for AMD treatment. Healios holds the RPE cell patent from RIKEN and collaborates with RACTHEra; Sighregen handles joint production and sales promotion.
• Yokohama City UniversitycoreStrategic or Co-development Partner · 1 January 2014Since 2014, Healios has collaborated with Yokohama City University on the production of functional human 3D liver organ buds using iPSC-derived organ progenitor cells co-cultured with mesenchymal stem cells and vascular endothelial cells. This represents a key platform technology partnership for liver disease treatment.
• Minaris (Contract Manufacturing Organization)coreImplementation/ SI/ Consulting PartnerHealios partnered with Minaris, a CMO specializing in stem cell and bioreactor-based manufacturing, to establish a commercial manufacturing facility equipped with a proprietary 50L bioreactor-based invimestrocel manufacturing process. This partnership is essential for obtaining marketing approval and producing commercial product.
• RACTHEra Co., Ltd.coreStrategic or Co-development PartnerRACTHEra Co., Ltd. entered into a joint development agreement with Healios for treatments for RPE tear and AMD using iPS cell-derived RPE cells. RACTHEra provides development capital while Healios obtains approval for production and sales, with products produced and sold jointly through Sighregen.
• Thomas Jefferson UniversitymoderateStrategic or Co-development PartnerJoint research collaboration with Thomas Jefferson University (Philadelphia, USA) on the efficacy of Healios' eNK cells against metastatic uveal melanoma. Results were presented at AACR Annual Meeting 2026. Healios and Akatsuki Therapeutics are jointly developing eNK cells with Thomas Jefferson University.
• Hyogo Medical UniversityminorStrategic or Co-development PartnerJoint research with Hyogo Medical University on the efficacy of eNK cells in mesothelioma. Research results were presented at AACR Annual Meeting 2024 and the 83rd Japanese Cancer Association Annual Meeting.
• National Cancer Center Research InstituteminorStrategic or Co-development PartnerCollaboration with the Division of Molecular Pharmacology at the National Cancer Center Research Institute on research related to gene-engineered iPSC-derived NK cells (HLCN061) for lung cancer treatment, presented at the 83rd Japanese Cancer Association Annual Meeting.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mesoblast: Australia-listed cell therapy company developing mesenchymal stem cell–based therapies (remestemcel-L) for inflammatory conditions including ARDS and acute graft-versus-host disease — directly comparable to Healios' MultiStem/HLCM051 (invimestrocel) for ARDS and stroke.
• Nkarta Therapeutics: Clinical-stage biotech developing off-the-shelf allogeneic NK cell therapies for hematologic malignancies and solid tumors, comparable in modality (gene-edited NK cells for cancer) and target indications to Healios' eNK program.
• Century Therapeutics: iPSC-derived allogeneic cell therapy company (gamma-delta T cells and NK cells) for oncology, with similar gene-editing and hypoimmunogenic cell strategies that overlap with Healios' eNK and UDC programs.
• Fate Therapeutics: US-based iPSC-derived cell therapy company developing engineered NK cell (and T cell) therapies for cancer, directly comparable to Healios' eNK platform and its multi-gene engineering approach (CD16, IL-15, CCR, etc.) to enhance anti-tumor activity.

Emerging players

• Cynata Therapeutics: Australian clinical-stage company developing iPSC-derived mesenchymal stem cell (MSC) therapies for inflammatory and immune conditions, comparable in platform modality (iPSC-derived allogeneic therapies) to Healios.
• Cytovia Therapeutics: Developer of iPSC-derived NK cells and CAR-NK therapies for solid tumors and hematologic cancers — overlaps with Healios' eNK program in target indication and cell engineering approach.

Broad incumbents

• Astellas Pharma: Major Japanese pharmaceutical company with growing investment in cell and gene therapy and regenerative medicine, including partnered programs. Comparable as a Japan-based large biopharma with strategic interests in the same regenerative-medicine space.
• Sumitomo Pharma: Large Japanese pharma that already participates in Healios' Sighregen JV for RPE cell commercialization, and operates in regenerative and cell therapy. A relevant broader incumbent both as collaborator and potential competitive counterparty in Japan.

Regional players

• Orizuru Therapeutics: Japan-based iPSC-regenerative-medicine startup (originating from Kyoto University/CiRA) developing iPSC-derived cardiomyocytes for heart failure — comparable iPSC-derived cell therapy focus but geographic peer focused on cardiovascular indications rather than Healios' broader pipeline.
• Heartseed Inc. Tokyo-listed Japanese biotech developing iPSC-derived cardiac progenitor cells for heart failure — shares Healios' iPSC-regenerative-medicine platform orientation and Japanese clinical development pathway under PMDA oversight.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/healiospr
• YouTubeyoutube.com/@healiosirpr8910
• LinkedInlinkedin.com/company/healios-k-k-

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries7 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healios